ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IDIX (MM)

24.50
0.00 (0.00%)
16 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:IDIX NASDAQ Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 24.50 0.00 01:00:00

Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences

07/03/2011 9:10pm

PR Newswire (US)


(MM) (NASDAQ:IDIX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more (MM) Charts.

CAMBRIDGE, Mass., March 7, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present a corporate overview at the Roth 23rd Annual Growth Stock Conference on Monday, March 14, 2011 at 12:00 p.m. PT at the Ritz Carlton Laguna Niguel in Dana Point, California and at the Barclays Capital 2011 Global Healthcare Conference on Thursday, March 17, 2011 at 11:15 a.m. ET at the Loews Miami Hotel, Florida.

The live and archived webcasts of the company presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com.  Please log in approximately 5-10 minutes before each event to ensure a timely connection.  The archived replays will be available on the Idenix website for two weeks following the conferences.  

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals Contact:

Kelly Barry (617) 995-9033 (media)

Eric Hoffman (617) 224-4485 (investors)





SOURCE Idenix Pharmaceuticals, Inc.

Copyright 2011 PR Newswire

1 Year (MM) Chart

1 Year (MM) Chart

1 Month (MM) Chart

1 Month (MM) Chart

Your Recent History

Delayed Upgrade Clock